US biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) announced on Monday that it has completed the transfer of the Investigational New Drug application (IND) for its breast cancer vaccine from Cleveland Clinic.
Anixa is now the trial sponsor for future development of the vaccine.
The company said that, with enrolment completed and encouraging immune response and safety data observed in the Phase 1 trial, it intends to advance the vaccine into a Phase 2 clinical trial and has assumed full sponsorship of the IND. Anixa is planning to use multiple clinical sites, including Cleveland Clinic, for the Phase 2 and other clinical trials.
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
GSK agrees US pricing framework to expand access to respiratory medicines
ECO Animal Health Group secures EU approval for ECOVAXXIN MS
Century Health partnerss with Tessel Biosciences to advance early drug development in COPD
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
BioNTech completes acquisition of CureVac
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Physiomics secures follow-on UK contract for Phase 2 study support
RedHill Biopharma reports positive opaganib data in venetoclax-resistant CLL
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China